Several mechanisms were reported for the acquired resistance to osimertinib in EGFR-T790M mutated NSCLC patients, including EGFR-C797S mutation, bypass signal activation, and transformation to small cell lung cancer [16,17,18]. Here, EGFR is linked to non-small cell lung carcinoma.